QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

CABA

QT57Cabaletta Bio, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
2.84
+0.00%
OverviewShort InterestFilings
CABAQT57Cabaletta Bio, Inc.·NASDAQ
OverviewShort InterestFilings
2.84+0.00%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-
Insider Own4.53%
Shs Outstand163.05M
Perf Week-5.65%
Market Cap463.08MForward P/E-EPS next Y-1.24Insider Trans0.08%Shs Float-Perf Month-13.15%
Enterprise Value372.89MPEG-EPS next Q-0.37Inst Own-Short Float-Perf Quarter-6.58%
Income-255339897.00P/S0.00EPS this Y-Inst Trans-Short Ratio-Perf Half Y18.83%
Sales-P/B3.08EPS next Y9.60%ROA-118.42%Short Interest-Perf YTD29.68%
Book/sh0.63P/C-EPS next 5Y-ROE-131.58%52W High4.23 -32.86%Perf Year51.87%
Cash/sh0.72P/FCF-EPS past 3/5Y-ROIC-138.26%52W Low1.26 125.40%Perf 3Y-
Dividend Est.-EV/EBITDA-2.17Sales past 3/5Y-Gross Margin0.00%Volatility5.29% 5.45%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM16.24%Oper. Margin0.00%ATR (14)0.26Perf 10Y-
Dividend Ex-Date-Quick Ratio2.95Sales Y/Y TTM-Profit Margin0.00%RSI (14)32.65Recom2.17
Dividend Gr. 3/5Y-Current Ratio2.95EPS Q/Q45.07%SMA20-15.35%Beta2.05Target Price16.33
Payout0.00%Debt/Eq0.26Sales Q/Q-SMA50-15.41%Rel Volume4.20Prev Close2.84
Employees161LT Debt/Eq0.03EarningsAug 06SMA2003.09%Avg Volume4.09MPrice2.84
IPO DateOct 25, 2019Option/ShortNo / YesEPS/Sales Surpr.4.88% -Net Debt/EBITDA0.53Volume17,176,359Change0.00%
Analyst Ratings
DateActionAnalystRatingTarget
Dec-20-24DowngradeEvercore ISI GroupOutperform → In Line
Dec-19-24DowngradeWells FargoOverweight → Equal Weight
Mar-21-24ReiteratedStifel Nicolaus$32
Jan-27-23UpgradeMorgan StanleyEqual Weight → Overweight
Jan-03-23ReiteratedWells FargoOverweight$14
Aug-30-22DowngradeMorgan StanleyOverweight → Equal Weight$3.00
Latest News
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
FY 2017
12/31/2017
Total Revenue
000
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A
000
Gross Profit
000
Selling, General and Administrative Excl. Other302819
Research and Development1439755
Other Operating Expense-101
Operating Income-172-125-75
Interest Expense210
Unusual Expense
———
Non-Operating Income (Expense)-6-10-7
Net Income Before Taxes-168-116-68
Income Taxes
000
Consolidated Net Income-168-116-68
Net Income From Continuing Operations-168-116-68
Net Income-168-116-68
EPS (Recurring)-1.64-2.34-1.65
EPS (Basic, Before Extraordinaries)-1.64-2.34-1.65
EPS (Diluted)-1.64-2.34-1.65
EBITDA-164-113-66
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio
———
Gross Margin
———
Operating Margin
———
Net Margin
———
Shares Outstanding1025041
Market Capitalization223——
Operating Lease Expense
———
Insider Trading Volume
$2.95$2.76$2.56$2.37$2.18● Close Price0.00K74.05K148.09K222.14K296.19KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Chang David J.Chief Medical OfficerJan 21 '26Buy2.268,80019,8888,800Jan 21 12:00 AM
Binder GwendolynPresident, Science & Tech.Jan 21 '26Buy2.1911,31224,76331,312Jan 21 12:00 AM
Tomasello ShawnDirectorJan 21 '26Buy2.2122,72550,32222,725Jan 21 12:00 AM
Gavel SteveChief Commercial OfficerJan 21 '26Buy2.2722,17050,21522,170Jan 21 12:00 AM
Bollard CatherineDirectorJan 21 '26Buy2.274,4059,9825,405Jan 21 12:00 AM
Nichtberger StevenPresident & CEOJan 21 '26Buy2.2445,000100,7781,031,483Jan 21 12:00 AM
Simon MarkDirectorJan 21 '26Buy2.2811,06125,261147,205Jan 21 12:00 AM
Gerard MichaelGeneral CounselJan 21 '26Buy2.276,60014,9796,600Jan 21 12:00 AM
Binder GwendolynSee RemarksJan 19 '24Option Exercise1.0122,00022,220100,756Jan 19 12:00 AM
Binder GwendolynSee RemarksJan 19 '24Sale19.5911,000215,44020,000Jan 19 12:00 AM
Binder GwendolynSee RemarksDec 19 '23Option Exercise1.0122,00022,220111,756Dec 19 12:00 AM
Binder GwendolynSee RemarksDec 19 '23Sale21.8911,000240,78920,000Dec 19 12:00 AM
Binder GwendolynSee RemarksNov 20 '23Option Exercise1.0122,00022,220122,756Nov 21 12:00 AM
Binder GwendolynSee RemarksNov 20 '23Sale17.8211,000196,01320,000Nov 21 12:00 AM
Binder GwendolynSee RemarksOct 19 '23Option Exercise1.0122,00022,220133,756Oct 19 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR